New Equity Network Radio Show Features FlutiCare(TM), Innovus Pharma’s Product for Allergic Rhinitis in an Exclusive Interview with President and CEO Dr. Bassam Damaj

SAN DIEGO, CA / ACCESSWIRE / June 10, 2015 / Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCQB: INNV)
a company focusing on the commercialization of over-the-counter (“OTC”)
and consumer products for men’s and women’s health, vitality and
respiratory diseases,announced today that Dr. Bassam Damaj, President andChief Executive Officer of the Company gave an exclusive interview to Michael Yorba, the host of the show on June 5th 2015. The interview can be viewed on the following link https://www.youtube.com/watch?v=hQ9VVXt0nhw.

The New Equity Network Radio Show is broadcast nationwide. In this exclusive interview, Dr. Damaj discussed the $1 billion market that FlutiCare(TM), a generic form of fluticasone propionate,will be entering into, if its OTC Abbreviated New Drug Application (“ADNA”) is approved by the U.S. Food & Drug Administration (“FDA”). He also discussed the potential approval timeline for FlutiCare(TM), which is currently expected to be around the first quarter of 2016. In addition to explaining the product, the market and the expected approval and launch date if approved by the FDA, Dr. Damaj detailed the potential launch in retails stores and the Company’s planned online membership program.

About FlutiCare(TM)

Fluticasone propionate 50 mcg
spray, is the No. 1 prescribed allergy treatment ingredient1 treatment
for temporary relief of the symptoms of hay fever or upper respiratory
allergies in the U.S.2Roughly 50 million people in the U.S. suffer from
nasal allergies3, and allergies take a toll on sufferers:

– Nasal allergies can lead to fatigue, sleep disturbances, learning
and attention problems and impaired function at work and/or school.4
– In 2010, Americans with allergic rhinitis (“AR”) spent approximately
$17.5 billion on health- related costs, lost more than 6 million work
and school days and made more than 16 million visits to the doctor.5
– 70 percent of sufferers treat their symptoms with prescription or
OTC treatments6; however, 50 percent of them report they are not
completely satisfied with their current method of treatment.7

References

[1] Sur D, et al. Treatment of Allergic Rhinitis. American Family Physician. Volume 81, Number 12, June 15, 2010.

[2] American College of Allergy, Asthma and Immunology: Allergy facts. Available at http://www.acaai.org/allergist/news/Pages/Allergy_Facts.aspx. Accessed July 2014.

[3] American College of Allergy, Asthma and Immunology: Allergic diseases and cognitive impairment. Available at http://www.acaai.org/allergist/allergies/Types/rhinitis/Pages/allergic-diseases-cognitive-impairment.aspx. Accessed July 2014.

[4] Academy of Allergy and Asthma in Primary Care: National impact of allergies. Available at http://www.aaapc.us/wp-content/uploads/2013/01/National-Impact-of-Allergies.pdf. Accessed July 2014.

[5] Scadding G, Punekar Y. EAACI 2006, Abstract 742.

[6] New Survey Reveals Many Patients Want More from Their Allergy
Medication. Asthma and Allergy Foundation of America. Available at:
http://www.aafa.org/display.cfm?id=7&sub=92&cont=529. Accessed
April 24, 2014[7] Data on hand

[7] Data on hand.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma
is an emerging leader in OTC and consumer products for men’s and
women’s health and vitality. The Company generates revenues from its
lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health, Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare(TM) OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to www.innovuspharma.com, www.zestra.com;
www.ejectdelay.com; www.myvesele.com; www.sensumplus.com;
www.myadroferti.com

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, receivingapproval
or to be compliant with the requirements of any relevant regulatory
authority, to successfully receive approval from the FDA of the OTC ANDA filed and to commercialize FlutiCare(TM) and other products and to achieve its other development,
commercialization, financial and staffing objectives.Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from
the SEC’s website or without charge from the Company.

Contact:

Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

SOURCE: Innovus Pharmaceuticals, Inc.

ReleaseID: 429698